{"id":894,"date":"2025-03-07T20:44:45","date_gmt":"2025-03-07T20:44:45","guid":{"rendered":"https:\/\/clinical.vervetrials.com\/?page_id=894"},"modified":"2026-03-13T16:56:05","modified_gmt":"2026-03-13T16:56:05","slug":"pulse-1","status":"publish","type":"page","link":"https:\/\/verveclinicaltrials.com\/fr\/pulse-1\/","title":{"rendered":"Pulse-1"},"content":{"rendered":"<main id='bde-main'><section class=\"bde-section-894-256 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-257 bde-columns\"><div class=\"bde-column-894-258 bde-column\">\n  \n  \n\t\n\n\n\n<h1 class=\"bde-heading-894-259 bde-heading\">\nContribuez \u00e0 fa\u00e7onner l'avenir du traitement de l'hypercholest\u00e9rol\u00e9mie\n<\/h1><div class=\"bde-text-894-260 bde-text\">\nParticiper \u00e0 l'\u00e9tude Pulse-1\n<\/div><div class=\"bde-text-894-261 bde-text\">\nL'\u00e9tude Pulse-1 permettra de d\u00e9terminer si une dose unique d'un m\u00e9dicament exp\u00e9rimental, appel\u00e9 VERVE-201, peut r\u00e9duire en toute s\u00e9curit\u00e9 le cholest\u00e9rol \u00e0 lipoprot\u00e9ines de basse densit\u00e9 (LDL-C), souvent appel\u00e9 \"mauvais\" cholest\u00e9rol, chez les personnes dont le LDL-C reste trop \u00e9lev\u00e9 m\u00eame apr\u00e8s avoir pris les m\u00e9dicaments actuellement disponibles. <br><br>Si votre taux de LDL-C reste trop \u00e9lev\u00e9, vous pourriez \u00eatre admissible \u00e0 participer \u00e0 l'\u00e9tude Pulse-1.\n<\/div><div class=\"bde-button-894-262 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify\" target=\"_self\" data-type=\"url\"  aria-label=\"See if you prequalify for the Pulse-1 study.\" >\n\n    \n        <span class=\"button-atom__text\">Aller \u00e0 la pr\u00e9s\u00e9lection<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div><div class=\"bde-button-894-263 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify-mobile\" target=\"_self\" data-type=\"url\"  aria-label=\"V\u00e9rifiez si vous remplissez les conditions requises pour participer \u00e0 l'\u00e9tude Pulse-1.\" >\n\n    \n        <span class=\"button-atom__text\">Aller \u00e0 la pr\u00e9s\u00e9lection<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div>\n<\/div><div class=\"bde-column-894-264 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-283 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_hero.jpg\" alt=\"\">\n<\/div><\/div><\/div>\n<\/section><nav class=\"bde-section-894-110 bde-section\" aria-label=\"content\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-div-894-111 bde-div\">\n              \n  \n  \n\t\n\n\n\n<div class=\"bde-menu-894-112 bde-menu\">\n\n\n      \n        \n    <nav class=\"breakdance-menu breakdance-menu--collapse\">\n    <button class=\"breakdance-menu-toggle breakdance-menu-toggle--squeeze\" type=\"button\" aria-label=\"Ouvrir le menu\" aria-expanded=\"false\" aria-controls=\"menu-112\">\n                  <span class=\"breakdance-menu-toggle-icon\">\n            <span class=\"breakdance-menu-toggle-lines\"><\/span>\n          <\/span>\n            <\/button>\n    \n  <ul class=\"breakdance-menu-list\" id=\"menu-112\">\n              \n  \n    <li class=\"bde-button-894-113 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-about\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">\u00c0 propos de l\u2019\u00e9tude<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-114 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-why-participate\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">Pourquoi participer?<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-115 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-what-to-expect\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">\u00c0 quoi s'attendre en participant \u00e0 l'\u00e9tude<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-116 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-participant-qualifications\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">Admissibilit\u00e9 des participants<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-117 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-qualify\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">V\u00e9rifiez votre pr\u00e9admissibilit\u00e9<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-118 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-details\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">D\u00e9tails de l'\u00e9tude<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li><li class=\"bde-button-894-119 bde-button breakdance-menu-item\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-locations\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">Lieux d\u2019\u00e9tude<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/li>\n  <\/ul>\n  <\/nav>\n\n\n<\/div>\n<\/div><\/div>\n<\/nav><section id=\"pulse-about\" class=\"bde-section-894-120 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-121 bde-columns\"><div class=\"bde-column-894-124 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-284 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_about.jpg\" alt=\"\"><h2 class=\"bde-heading-894-125 bde-heading\">\n\u00c0 propos de l'\u00e9tude Pulse-1\n<\/h2><div class=\"bde-rich-text-894-126 bde-rich-text breakdance-rich-text-styles\">\n<p>L'\u00e9tude Pulse-1 est un essai clinique de phase 1b auquel participent des personnes pr\u00e9sentant un risque \u00e9lev\u00e9 d'\u00e9v\u00e9nements cardiovasculaires graves, tels qu'une crise cardiaque ou un accident vasculaire c\u00e9r\u00e9bral, en raison d'un taux de cholest\u00e9rol \u00e9lev\u00e9. L'\u00e9tude Pulse-1 permettra de d\u00e9terminer si une dose unique d'un m\u00e9dicament exp\u00e9rimental, appel\u00e9 VERVE-201, peut r\u00e9duire en toute s\u00e9curit\u00e9 le cholest\u00e9rol \u00e0 lipoprot\u00e9ines de basse densit\u00e9 (LDL-C) chez les personnes dont le LDL-C reste \u00e9lev\u00e9 m\u00eame apr\u00e8s avoir pris les m\u00e9dicaments actuellement disponibles.<br \/><br \/>Un taux \u00e9lev\u00e9 de LDL-C augmente le risque d'\u00e9v\u00e9nements cardiovasculaires graves, tels qu'une crise cardiaque ou un accident vasculaire c\u00e9r\u00e9bral. L'abaissement du taux de LDL-C est l'un des meilleurs moyens de r\u00e9duire ces risques. <br \/><br \/>Jusqu'\u00e0 36 personnes dans plusieurs pays prendront part \u00e0 l'\u00e9tude Pulse-1. Les participants seront impliqu\u00e9s dans l'essai jusqu'\u00e0 un an apr\u00e8s avoir re\u00e7u VERVE-201. \u00c0 l'issue de l'\u00e9tude, il est pr\u00e9vu que les participants se joignent \u00e0 une \u00e9tude de suivi \u00e0 long terme afin d'aider les chercheurs \u00e0 comprendre l'innocuit\u00e9 de VERVE-201 sur une p\u00e9riode plus longue.<\/p>\n<\/div>\n<\/div><\/div><div class=\"bde-div-894-127 bde-div\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-128 bde-heading\">\n\u00c0 propos du m\u00e9dicament exp\u00e9rimental\n<\/h2><div class=\"bde-text-894-129 bde-text translation-block\">VERVE-201, le m\u00e9dicament exp\u00e9rimental utilisant la technologie d\u2019\u00e9dition g\u00e9n\u00e9tique, est administr\u00e9 une fois par perfusion intraveineuse (IV) dans une veine du bras. VERVE-201 est con\u00e7u pour d\u00e9sactiver de fa\u00e7on permanente un g\u00e9ne appel\u00e9 ANGPTL3 dans le foie. D\u2019autres m\u00e9dicaments bloquant l'activit\u00e9 de l'ANGPTL3 se sont r\u00e9v\u00e9l\u00e9s s\u00fbrs et etticaces pour abaisser le taux de LDL-C. La technologie d'edition de g\u00e9nes \u00e0 l'\u00e9tude a le potentiel de r\u00e9duire les niveaux de LDL-C pendant de nombreuses ann\u00e9es a pr\u00e9s une seule dose.<br \/>\n<br \/>L'essai clinique a \u00e9t\u00e9 approuv\u00e9 par un comit\u00e9 d\u2019examen institutionnel\/\u00e9thique et une autorit\u00e9 sanitaire nationale, qui prot\u00e8ge les droits, la s\u00e9curit\u00e9 et le bein-\u00e9tre des participants.<\/div><div id=\"brochure-en\" class=\"bde-button-894-130 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"\/wp-content\/uploads\/2025\/02\/Pulse-1_PatientBrochure_Digital_15Jan2025_-V1.0.pdf\" target=\"_self\" data-type=\"url\"  aria-label=\"Download the brochure about the investigational medicine\" >\n\n    \n        <span class=\"button-atom__text\">T\u00e9l\u00e9charger la brochure<\/span>\n\n                            \n        \n                <\/a>\n\n    \n\n\n<\/div>\n<\/div><\/div>\n<\/section><section class=\"bde-section-894-131 bde-section\">\n              \n  \n  \n\t\n\n  <div class=\"section-background-overlay\"><\/div>\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-132 bde-columns\"><div class=\"bde-column-894-133 bde-column\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-134 bde-heading\">\nTaux \u00e9lev\u00e9 de LDL-C et maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques (MCVA)\n<\/h2><div class=\"bde-text-894-135 bde-text\">\nUn taux \u00e9lev\u00e9 de LDL-C circulant dans le sang est l'une des principales causes des maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques (MCVA). Les maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques sont un terme g\u00e9n\u00e9ral d\u00e9signant les affections caus\u00e9es par l'accumulation de plaques de cholest\u00e9rol dans les art\u00e8res. Si l'accumulation de la plaque devient importante, elle peut restreindre la circulation sanguine et entra\u00eener des \u00e9v\u00e9nements graves tels qu'une crise cardiaque ou un accident vasculaire c\u00e9r\u00e9bral. Un taux tr\u00e8s \u00e9lev\u00e9 de LDL-C, d\u00e9fini comme un taux sup\u00e9rieur \u00e0 190 mg\/dl ou 4,9 mmol\/L, est consid\u00e9r\u00e9 comme une hypercholest\u00e9rol\u00e9mie s\u00e9v\u00e8re.<br><br>L'un des moyens les plus efficaces de r\u00e9duire le risque d'\u00e9v\u00e9nements, tels que les crises cardiaques et les accidents vasculaires c\u00e9r\u00e9braux, consiste \u00e0 abaisser le taux de LDL-C dans le sang en dessous des objectifs m\u00e9dicalement recommand\u00e9s. Certaines personnes ont un taux de LDL-C qui reste sup\u00e9rieur \u00e0 l'objectif fix\u00e9, m\u00eame apr\u00e8s avoir modifi\u00e9 leur mode de vie et pris les m\u00e9dicaments hypocholest\u00e9rol\u00e9miants actuellement disponibles. Ces personnes pr\u00e9sentent un risque plus \u00e9lev\u00e9 que les patients qui atteignent ces objectifs.\n<\/div>\n<\/div><div class=\"bde-column-894-136 bde-column\">\n  \n  \n\t\n\n\n\n\n<\/div><\/div><\/div>\n<\/section><section class=\"bde-section-894-266 bde-section\">\n              \n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-267 bde-columns\"><div class=\"bde-column-894-268 bde-column\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-269 bde-heading\">\nTaux \u00e9lev\u00e9 de LDL-C et maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques (MCVA)\n<\/h2><div class=\"bde-text-894-270 bde-text\">\nUn taux \u00e9lev\u00e9 de LDL-C circulant dans le sang est l'une des principales causes des maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques (MCVA). Les maladies cardiovasculaires ath\u00e9roscl\u00e9rotiques sont un terme g\u00e9n\u00e9ral d\u00e9signant les affections caus\u00e9es par l'accumulation de plaques de cholest\u00e9rol dans les art\u00e8res. Si l'accumulation de la plaque devient importante, elle peut restreindre la circulation sanguine et entra\u00eener des \u00e9v\u00e9nements graves tels qu'une crise cardiaque ou un accident vasculaire c\u00e9r\u00e9bral. Un taux tr\u00e8s \u00e9lev\u00e9 de LDL-C, d\u00e9fini comme un taux sup\u00e9rieur \u00e0 190 mg\/dl ou 4,9 mmol\/L, est consid\u00e9r\u00e9 comme une hypercholest\u00e9rol\u00e9mie s\u00e9v\u00e8re.<br><br>L'un des moyens les plus efficaces de r\u00e9duire le risque d'\u00e9v\u00e9nements, tels que les crises cardiaques et les accidents vasculaires c\u00e9r\u00e9braux, consiste \u00e0 abaisser le taux de LDL-C dans le sang en dessous des objectifs m\u00e9dicalement recommand\u00e9s. Certaines personnes ont un taux de LDL-C qui reste sup\u00e9rieur \u00e0 l'objectif fix\u00e9, m\u00eame apr\u00e8s avoir modifi\u00e9 leur mode de vie et pris les m\u00e9dicaments hypocholest\u00e9rol\u00e9miants actuellement disponibles. Ces personnes pr\u00e9sentent un risque plus \u00e9lev\u00e9 que les patients qui atteignent ces objectifs.\n<\/div>\n<\/div><div class=\"bde-column-894-271 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-272 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_block-alt.png\" alt=\"\" srcset=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_block-alt.png 700w, https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_block-alt-300x236.png 300w, https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_block-alt-15x12.png 15w\" sizes=\"(max-width: 700px) 100vw, 700px\">\n<\/div><\/div><\/div>\n<\/section><section id=\"pulse-why-participate\" class=\"bde-section-894-138 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-139 bde-columns\"><div class=\"bde-column-894-140 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-285 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_why.png\" alt=\"\">\n<\/div><div class=\"bde-column-894-142 bde-column\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-143 bde-heading\">\nPourquoi participer?\n<\/h2><div class=\"bde-rich-text-894-144 bde-rich-text breakdance-rich-text-styles\">\n<p>Les participants \u00e0 l'\u00e9tude Pulse-1 auront la possibilit\u00e9 de contribuer au d\u00e9veloppement d'un nouveau m\u00e9dicament potentiel qui pourrait les aider, ainsi que d'autres personnes pr\u00e9sentant un taux \u00e9lev\u00e9 de LDL-C, y compris peut-\u00eatre des membres de leur famille, \u00e0 l'avenir. Les participants \u00e0 l'\u00e9tude recevront VERVE-201, qui pourrait r\u00e9duire de fa\u00e7on permanente les taux de LDL-C. Il est toutefois important de noter que la s\u00e9curit\u00e9 et l'efficacit\u00e9 de VERVE-201 sont encore \u00e0 l'\u00e9tude.<\/p>\n<\/div><div class=\"bde-button-894-145 bde-button\">\n        \n    \n    \n    \n              \n            \n                    \n            \n            \n\n    \n    \n    \n    \n              \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">Aller \u00e0 la pr\u00e9s\u00e9lection<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div><div class=\"bde-button-894-146 bde-button\">\n        \n    \n    \n    \n    \n            \n                    \n            \n            \n\n    \n    \n    \n    \n    \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify-mobile\" target=\"_self\" data-type=\"url\"  >\n\n    \n        <span class=\"button-atom__text\">Aller \u00e0 la pr\u00e9s\u00e9lection<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div>\n<\/div><\/div><\/div>\n<\/section><section class=\"bde-section-894-147 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><\/div>\n<\/section><section id=\"pulse-what-to-expect\" class=\"bde-section-894-150 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><h2 class=\"bde-heading-894-151 bde-heading\">\n\u00c0 quoi s'attendre en participant \u00e0 l'\u00e9tude Pulse-1 ?\n<\/h2><div class=\"bde-grid-894-152 bde-grid\">\n  \n  \n\t\n\n\n\n<div class=\"bde-div-894-153 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-273 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1-warning.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1-warning.webp 165w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1-warning-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1-warning-12x12.webp 12w\" sizes=\"(max-width: 165px) 100vw, 165px\"><div class=\"bde-text-894-155 bde-text\">\nL'\u00e9quipe de l'essai clinique expliquera les avantages et les risques possibles de la participation\n<\/div>\n<\/div><div class=\"bde-div-894-156 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-274 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-1.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-1.webp 165w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-1-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-1-12x12.webp 12w\" sizes=\"(max-width: 165px) 100vw, 165px\"><div class=\"bde-text-894-158 bde-text\">\nSi vous choisissez de participer \u00e0 un essai clinique, vous pouvez arr\u00eater de participer \u00e0 tout moment\n<\/div>\n<\/div><div class=\"bde-div-894-159 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-275 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-2.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-2.webp 165w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-2-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-2-12x12.webp 12w\" sizes=\"(max-width: 165px) 100vw, 165px\"><div class=\"bde-text-894-161 bde-text\">\nVous serez rembours\u00e9 pour votre temps de participation\n<\/div>\n<\/div><div class=\"bde-div-894-162 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-276 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-3.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-3.webp 165w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-3-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-3-12x12.webp 12w\" sizes=\"(max-width: 165px) 100vw, 165px\"><div class=\"bde-text-894-164 bde-text\">\nVous serez rembours\u00e9 pour les frais de voyage ou autres d\u00e9penses encourues lors de votre participation\n<\/div>\n<\/div><div class=\"bde-div-894-165 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-277 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-4-2.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-4-2.webp 164w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-4-2-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-4-2-12x12.webp 12w\" sizes=\"(max-width: 164px) 100vw, 164px\"><div class=\"bde-text-894-167 bde-text\">\nVERVE-201 et les tests li\u00e9s \u00e0 l'essai clinique seront fournis gratuitement aux participants\n<\/div>\n<\/div><div class=\"bde-div-894-168 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-278 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-5.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-5.webp 164w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-5-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-5-12x12.webp 12w\" sizes=\"(max-width: 164px) 100vw, 164px\"><div class=\"bde-text-894-170 bde-text\">\nUne \u00e9quipe de m\u00e9decins et d'infirmi\u00e8res de l'\u00e9tude suivra attentivement votre \u00e9tat de sant\u00e9 pendant votre participation\n<\/div>\n<\/div><div class=\"bde-div-894-171 bde-div\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-279 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-6.webp\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-6.webp 164w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-6-150x150.webp 150w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/pulse-1_expect-6-12x12.webp 12w\" sizes=\"(max-width: 164px) 100vw, 164px\"><div class=\"bde-text-894-173 bde-text\">\nL'\u00e9tude a \u00e9t\u00e9 approuv\u00e9e par un comit\u00e9 d'examen institutionnel\/\u00e9thique et une autorit\u00e9 sanitaire nationale, qui prot\u00e8gent les droits, la s\u00e9curit\u00e9 et le bien-\u00eatre des participants\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/section><section id=\"pulse-participant-qualifications\" class=\"bde-section-894-174 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-columns-894-175 bde-columns\"><div class=\"bde-column-894-176 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-286 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-1_qualify.png\" alt=\"\">\n<\/div><div class=\"bde-column-894-178 bde-column\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-179 bde-heading\">\nAdmissibilit\u00e9 des participants\n<\/h2><div class=\"bde-text-894-180 bde-text\">\nVous pourriez \u00eatre admissible \u00e0 participer si vous* :\n<\/div><div class=\"bde-columns-894-181 bde-columns\"><div class=\"bde-column-894-182 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-288 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-icon-blue.png\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-icon-blue.png 53w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-icon-blue-14x12.png 14w\" sizes=\"(max-width: 53px) 100vw, 53px\">\n<\/div><div class=\"bde-column-894-184 bde-column\">\n  \n  \n\t\n\n\n\n<div class=\"bde-text-894-185 bde-text\">\n\u00cates \u00e2g\u00e9 entre 18 et 70 ans\n<\/div>\n<\/div><\/div><div class=\"bde-columns-894-186 bde-columns\"><div class=\"bde-column-894-187 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-289 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-heart-blue.png\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-heart-blue.png 50w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-heart-blue-13x12.png 13w\" sizes=\"(max-width: 50px) 100vw, 50px\">\n<\/div><div class=\"bde-column-894-189 bde-column\">\n  \n  \n\t\n\n\n\n<div class=\"bde-text-894-190 bde-text\">\navez des ant\u00e9c\u00e9dents m\u00e9dicaux de l'une ou l'autre de ces maladies :\n<\/div><div class=\"bde-text-894-191 bde-text\">\nUn taux de cholest\u00e9rol tr\u00e8s \u00e9lev\u00e9, connu sous le nom de <br>hypercholest\u00e9rol\u00e9mie s\u00e9v\u00e8re\n<\/div><div class=\"bde-text-894-192 bde-text\">\nOU\n<\/div><div class=\"bde-text-894-193 bde-text\">\nUne MCVA (par exemple, crise cardiaque, accident vasculaire c\u00e9r\u00e9bral, pose d'une endoproth\u00e8se ou pontage pour ouvrir un vaisseau sanguin obstru\u00e9)\n<\/div>\n<\/div><\/div><div class=\"bde-columns-894-194 bde-columns\"><div class=\"bde-column-894-195 bde-column\">\n  \n  \n\t\n\n\n\n<img decoding=\"async\" class=\"bde-image2-894-290 bde-image2\" src=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-blood-blue.png\" alt=\"\" srcset=\"https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-blood-blue.png 48w, https:\/\/verveclinicaltrials.com\/wp-content\/uploads\/sites\/25\/2026\/03\/qualifications-blood-blue-11x12.png 11w\" sizes=\"(max-width: 48px) 100vw, 48px\">\n<\/div><div class=\"bde-column-894-197 bde-column\">\n  \n  \n\t\n\n\n\n<div class=\"bde-text-894-198 bde-text\">\npr\u00e9sentez des taux de LDL-C qui restent trop \u00e9lev\u00e9s m\u00eame apr\u00e8s avoir pris les m\u00e9dicaments disponibles pour abaisser le taux de LDL-C.\n<\/div><div class=\"bde-text-894-199 bde-text\">\n(comme les statines et\/ou les inhibiteurs de PCSK9)\n<\/div><div class=\"bde-text-894-200 bde-text\">\nCertaines personnes ne peuvent pas prendre ces m\u00e9dicaments en raison de leurs effets secondaires ou n'ont pas acc\u00e8s \u00e0 ces m\u00e9dicaments. Si c'est votre cas, vous pouvez quand m\u00eame participer.\n<\/div><div class=\"bde-text-894-201 bde-text\">\n*Des crit\u00e8res d'admissibilit\u00e9 suppl\u00e9mentaires s'appliquent\n<\/div>\n<\/div><\/div><div class=\"bde-button-894-202 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify\" target=\"_self\" data-type=\"url\"  aria-label=\"See if you prequalify for the Pulse-1 study.\" >\n\n    \n        <span class=\"button-atom__text\">V\u00e9rifiez votre pr\u00e9admissibilit\u00e9<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div><div class=\"bde-button-894-203 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--secondary bde-button__button\" href=\"#pulse-qualify-mobile\" target=\"_self\" data-type=\"url\"  aria-label=\"V\u00e9rifiez si vous remplissez les conditions requises pour participer \u00e0 l'\u00e9tude Pulse-1.\" >\n\n    \n        <span class=\"button-atom__text\">V\u00e9rifiez votre pr\u00e9admissibilit\u00e9<\/span>\n\n        \n        \n                <\/a>\n\n    \n\n\n<\/div>\n<\/div><\/div><\/div>\n<\/section><section id=\"pulse-qualify\" class=\"bde-section-894-204 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-div-894-205 bde-div\">\n  \n  \n\t\n\n\n\n<div class=\"bde-columns-894-206 bde-columns\"><div class=\"bde-column-894-207 bde-column\">\n  \n  \n\t\n\n\n\n\n<\/div><div class=\"bde-column-894-208 bde-column\">\n  \n  \n\t\n\n\n\n<h3 class=\"bde-heading-894-209 bde-heading\">\nV\u00e9rifiez votre pr\u00e9admissibilit\u00e9\n<\/h3><div class=\"bde-text-894-210 bde-text\">\nR\u00e9pondez \u00e0 quelques questions pour savoir si vous pouvez participer \u00e0 un essai clinique.\n<\/div><div class=\"bde-rich-text-894-213 bde-rich-text breakdance-rich-text-styles\">\n<p>Vos informations sont stock\u00e9es dans une base de donn\u00e9es conforme \u00e0 la loi HIPAA et fournies aux sites d'essai pour le suivi, le cas \u00e9ch\u00e9ant. Pour plus d'informations, veuillez consulter notre page sur la politique de protection de la vie priv\u00e9e. <a href=\"https:\/\/privacynotice.lilly.com\/global\/\" target=\"_blank\" rel=\"noopener\">veuillez consulter notre page sur la politique de protection de la vie priv\u00e9e<\/a>.<\/p>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/section><section id=\"qualify\" class=\"bde-section-894-214 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><img decoding=\"async\" class=\"bde-image2-894-287 bde-image2\" src=\"https:\/\/pulse1study.com\/wp-content\/uploads\/2025\/01\/pulse-prequalify.jpg\" alt=\"\"><\/div>\n<\/section><section id=\"pulse-qualify-mobile\" class=\"bde-section-894-216 bde-section\">\n              \n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-div-894-217 bde-div\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-218 bde-heading\">\nV\u00e9rifiez votre pr\u00e9admissibilit\u00e9\n<\/h2><div class=\"bde-text-894-219 bde-text\">\nR\u00e9pondez \u00e0 quelques questions pour savoir si vous pouvez participer \u00e0 un essai clinique.\n<\/div><div class=\"bde-rich-text-894-222 bde-rich-text breakdance-rich-text-styles\">\nVos informations sont stock\u00e9es dans une base de donn\u00e9es conforme \u00e0 la loi HIPPA et fournies aux sites d'essai pour un suivi le cas \u00e9ch\u00e9ant. Pour plus d'informations, <a href=\"https:\/\/privacynotice.lilly.com\/global\/\" target=\"_blank\">veuillez consulter notre page sur la politique de protection de la vie priv\u00e9e<\/a>.\n<\/div>\n<\/div><\/div>\n<\/section><section id=\"pulse-details\" class=\"bde-section-894-223 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><div class=\"bde-div-894-224 bde-div\">\n  \n  \n\t\n\n\n\n<h2 class=\"bde-heading-894-225 bde-heading\">\nP\u00e9riodes d'\u00e9tudes\n<\/h2><div class=\"bde-code-block-894-292 bde-code-block\">\n\n  <style>\n  .study-periods-list {\n    list-style: none;\n    padding: 0 !important;\n    margin: 0 !important;\n  }\n  .study-periods-list > li {\n    display: flex !important;\n    gap: 2rem;\n    align-items: center;\n    border-bottom: 1px solid rgba(0,0,0,0.2);\n    padding: 1.5rem 0 !important;\n    margin: 0 0 1.5rem 0 !important;\n  }\n  .study-periods-list > li:last-child {\n    border-bottom: none;\n    padding-bottom: 0;\n    margin-bottom: 0 !important;\n  }\n  .study-periods__number-1,\n  .study-periods__number-2,\n  .study-periods__number-3 {\n    display: inline-flex;\n    align-items: center;\n    justify-content: center;\n    text-align: center;\n    font-family: \"Prompt\", sans-serif;\n    font-size: 14rem;\n    width: 15%;\n    flex-shrink: 0;\n    align-self: center;\n    line-height: 1 !important;\n  }\n  .study-periods__number-1 { color: #961F8E; }\n  .study-periods__number-2 { color: #11ABE1; }\n  .study-periods__number-3 { color: #8BC344; }\n  .study-periods__content {\n    flex: 1;\n  }\n  .study-periods__title {\n    color: #11ABE1 !important;\n    font-size: 1.5em !important;\n    font-weight: 500 !important;\n    margin-top: 0;\n    margin-bottom: 10px;\n  }\n  .study-periods__duration {\n    margin: 0 0 0.75rem;\n  }\n  .study-periods__body {\n    margin: 0 0 0.75rem;\n  }\n  .study-periods__bullets {\n    padding-left: 2.5rem;\n    margin: 0;\n    list-style-type: disc;\n  }\n  .study-periods__bullets li::marker {\n    color: #000;\n  }\n  @media (max-width: 768px) {\n    .study-periods__number-1,\n    .study-periods__number-2,\n    .study-periods__number-3 {\n      font-size: 6rem;\n      width: 20%;\n    }\n    .study-periods-list > li {\n      gap: 1rem;\n    }\n  }\n  @media (max-width: 480px) {\n    .study-periods__number-1,\n    .study-periods__number-2,\n    .study-periods__number-3 {\n      font-size: 4rem;\n      width: 20%;\n    }\n  }\n<\/style>\n\n<ol class=\"study-periods-list\" style=\"padding:0;\">\n  <li>\n    <div class=\"study-periods__number-1\">1<\/div>\n    <div class=\"study-periods__content\">\n      <h3 class=\"study-periods__title\">P\u00e9riode de s\u00e9lection<\/h3>\n      <p class=\"study-periods__duration\">(jusqu'\u00e0 trois mois)<\/p>\n      <p class=\"study-periods__body\"><strong>Vous participerez \u00e0 des rendez-vous de s\u00e9lection pour d\u00e9terminer votre admissibilit\u00e9 \u00e0 l\u2019essai. Au cours de ces rendez-vous, plusieurs tests seront effectu\u00e9s, notamment des prises de sang et des examens physiques.<\/strong><\/p>\n      <ul class=\"study-periods__bullets\">\n        <li>Vous visiterez le site de l'\u00e9tude deux fois ou plus pour d\u00e9terminer si l'\u00e9tude vous convient. Si vous \u00eates admissible, vous aurez la possibilit\u00e9 de participer \u00e0 l'\u00e9tude.<\/li>\n        <li>Les visites de d\u00e9pistage doivent avoir lieu dans un d\u00e9lai de trois mois.<\/li>\n      <\/ul>\n    <\/div>\n  <\/li>\n  <li>\n    <div class=\"study-periods__number-2\">2<\/div>\n    <div class=\"study-periods__content\">\n      <h3 class=\"study-periods__title\">P\u00e9riode de traitement de l'\u00e9tude<\/h3>\n      <p class=\"study-periods__duration\">(environ deux jours)<\/p>\n      <p class=\"study-periods__body\"><strong>Si vous \u00eates admissible et d\u00e9cidez de participer, la p\u00e9riode de traitement de l'\u00e9tude impliquera un s\u00e9jour d'environ quatre jours\/trois nuits sur le site de l'\u00e9tude, au cours duquel :<\/strong><\/p>\n      <ul class=\"study-periods__bullets\">\n        <li>Vous recevrez une dose unique de VERVE-201 en perfusion IV dans votre bras.<\/li>\n        <li>Le personnel de l'\u00e9tude surveillera votre \u00e9tat de sant\u00e9 et proc\u00e9dera \u00e0 des \u00e9valuations similaires \u00e0 celles de la p\u00e9riode de s\u00e9lection afin de v\u00e9rifier si vous tol\u00e9rez bien VERVE-201. Si n\u00e9cessaire, votre s\u00e9jour pourra \u00eatre prolong\u00e9 pour une surveillance suppl\u00e9mentaire.<\/li>\n      <\/ul>\n    <\/div>\n  <\/li>\n  <li>\n    <div class=\"study-periods__number-3\">3<\/div>\n    <div class=\"study-periods__content\">\n      <h3 class=\"study-periods__title\">P\u00e9riode de suivi<\/h3>\n      <p class=\"study-periods__duration\">(environ un an)<\/p>\n      <ul class=\"study-periods__bullets\">\n        <li>Il y aura jusqu'\u00e0 11 visites de suivi au cours de l'ann\u00e9e suivant l'administration de VERVE-201 afin de continuer \u00e0 surveiller votre \u00e9tat de sant\u00e9, y compris la visite de fin d'\u00e9tude.<\/li>\n        <li>Apr\u00e8s la visite de fin d'\u00e9tude, vous continuerez \u00e0 participer \u00e0 une \u00e9tude de suivi \u00e0 long terme pour surveiller votre s\u00e9curit\u00e9 et votre taux de cholest\u00e9rol. La plupart de ces visites pourront \u00eatre effectu\u00e9es \u00e0 domicile.<\/li>\n      <\/ul>\n    <\/div>\n  <\/li>\n<\/ol>\n\n\n<\/div>\n<\/div><\/div>\n<\/section><section id=\"pulse-locations\" class=\"bde-section-894-251 bde-section\">\n  \n  \n\t\n\n\n\n<div class=\"section-container\"><h2 class=\"bde-heading-894-252 bde-heading\">\nEmplacement des centres d'\u00e9tude\n<\/h2><div class=\"bde-shortcode-894-253 bde-shortcode\"><style>\r\n\t#wpsl-stores .wpsl-store-thumb {height:45px !important; width:45px !important;}\r\n\t#wpsl-stores, #wpsl-direction-details, #wpsl-gmap {height:500px !important;}\r\n\t#wpsl-gmap .wpsl-info-window {max-width:225px !important;}\r\n\t.wpsl-input label, #wpsl-radius label, #wpsl-category label {width:150px;}\r\n\t#wpsl-search-input  {width:179px;}\r\n<\/style>\r\n<div id=\"wpsl-wrap\">\r\n\t<div class=\"wpsl-search wpsl-clearfix\">\r\n\t\t<div id=\"wpsl-search-wrap\">\r\n\t\t\t<form autocomplete=\"off\" action=\"\">\r\n\t\t\t<div class=\"wpsl-input\">\r\n\t\t\t\t<div><label for=\"wpsl-search-input\">Votre emplacement<\/label><\/div>\r\n\t\t\t\t<input id=\"wpsl-search-input\" type=\"text\" value=\"\" name=\"wpsl-search-input\" placeholder=\"\" aria-required=\"true\" \/>\r\n\t\t\t<\/div>\r\n\t\t\t<div class=\"wpsl-select-wrap\">\r\n\t\t\t\t<div id=\"wpsl-radius\">\r\n\t\t\t\t\t<label for=\"wpsl-radius-dropdown\">Rayon de recherche<\/label>\r\n\t\t\t\t\t<select id=\"wpsl-radius-dropdown\" class=\"wpsl-dropdown\" name=\"wpsl-radius\">\r\n\t\t\t\t\t\t<option value=\"10\">10 km<\/option><option value=\"25\">25 km<\/option><option selected=\"selected\" value=\"50\">50 km<\/option><option value=\"100\">100 km<\/option><option value=\"200\">200 km<\/option><option value=\"500\">500 km<\/option>\r\n\t\t\t\t\t<\/select>\r\n\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\t<div class=\"wpsl-search-btn-wrap\"><input id=\"wpsl-search-btn\" type=\"submit\" value=\"Recherche\"><\/div>\r\n\t\t<input type=\"hidden\" name=\"trp-form-language\" value=\"fr\"\/><\/form>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div id=\"wpsl-gmap\" class=\"wpsl-gmap-canvas\"><\/div>\r\n\t<div id=\"wpsl-result-list\">\r\n\t\t<div id=\"wpsl-stores\" >\r\n\t\t\t<ul><\/ul>\r\n\t\t<\/div>\r\n\t\t<div id=\"wpsl-direction-details\">\r\n\t\t\t<ul><\/ul>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n<\/div><div class=\"bde-button-894-254 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-qualify\" target=\"_self\" data-type=\"url\"  aria-label=\"See if you prequalify for the Pulse-1 study.\" >\n\n    \n        <span class=\"button-atom__text\">V\u00e9rifiez votre pr\u00e9admissibilit\u00e9<\/span>\n\n                            \n        \n                <\/a>\n\n    \n\n\n<\/div><div class=\"bde-button-894-255 bde-button\">\n        \n    \n    \n    \n                            \n            \n                    \n            \n            \n\n    \n    \n    \n    \n                            \n    <a class=\"breakdance-link button-atom button-atom--custom bde-button__button\" href=\"#pulse-qualify-mobile\" target=\"_self\" data-type=\"url\"  aria-label=\"V\u00e9rifiez si vous remplissez les conditions requises pour participer \u00e0 l'\u00e9tude Pulse-1.\" >\n\n    \n        <span class=\"button-atom__text\">V\u00e9rifiez votre pr\u00e9admissibilit\u00e9<\/span>\n\n                            \n        \n                <\/a>\n\n    \n\n\n<\/div><\/div>\n<\/section><\/main>","protected":false},"excerpt":{"rendered":"<p>Help shape the future of high cholesterol treatment Be part of the Pulse-1 study The Pulse-1 study will help determine if a single dose of an investigational medicine, called VERVE-201, can safely reduce low-density lipoprotein cholesterol (LDL-C), often referred to as \u2018bad\u2019 cholesterol, in people whose LDL-C remains too high even after taking currently available [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"_breakdance_hide_in_design_set":false,"_breakdance_tags":"","footnotes":""},"class_list":["post-894","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/pages\/894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/comments?post=894"}],"version-history":[{"count":67,"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/pages\/894\/revisions"}],"predecessor-version":[{"id":1283,"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/pages\/894\/revisions\/1283"}],"wp:attachment":[{"href":"https:\/\/verveclinicaltrials.com\/fr\/wp-json\/wp\/v2\/media?parent=894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}